Validation of FDA's RSABE on NTIDs [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2017-08-22 22:25 (2487 d 19:21 ago) – Posting: # 17739
Views: 15,775

Hi Zhang Yong,

❝ Hope you are well.

THX! Below my results obtained in Phoenix WinNonlin 7.0 in full precision.

❝ I manually calculate the sWR and sWT in Excel sheet, they are 0.124392769, 0.055720909, respectively. Are my results EXACTELY right?

swR 0.124392768691665, swT 0.0557209092013223

❝ In your slides, you have present the upper 95% CL of sWT/sWR 0.68427 ≤2.5.

❝ I have calculated

❝ lower 95% CL of sWT/sWR = 0.293238292

❝ upper 95% CL of sWT/sWR = 0.684266753 (this is nearly the same as your result)

lower CL 0.293238291752988, upper CL 0.684266752752176

❝ As US FDA's Guidance on Warfarin required, the upper 90% CI should be used, I also calculate the following:

❝ lower 90% CL of sWT/sWR = 0.322597242

❝ upper 90% CL of sWT/sWR = 0.621992961

❝ Are the above results right?

The guidance might be confusing. See the last bullet point below the formulaHence, 1–0.05 and 1–0.95 are correct.

❝ I use the function Finv(0.1,16,16) and Finv(0.9,16,16) for the calculation of 90% CL of sWT/sWR,

❝ and Finv(0.05,16,16) and Finv(0.95,16,16) for the calculation of 95% CL of sWT/sWR. Do I use the right function?

I have only Excel 2000. :-D Up to v2003 the inverse distributions were wrong. Maybe you have to use F.inv(alpha,df1,df1) or the old workaround Finv(2*alpha,df1,df1). Duno. The correct F-values (ν12=16) are:
Fα∕2,ν12 2.33348362746764, F1−α∕2,ν12 0.428543825304327

❝ Would you please guide (step by step) me how to calculate CVwr CVwt? As shown in your slides, they are CVWR 12.49%, CVWT 5.58%. Although these two values are not used in calculation of "upper 90% CL of sWT/sWR".

According to the guidance sWR and swT are estimated from complete data only (not an issue with this data set) ignoring its structure (solely 'sequence' in the linear model). Your values are correct. Hence, as usual \(CV = \sqrt{e^{s_{w}^{2}} - 1}\). Therefore, we get CVwR 12.49% and CVwT 5.58%.

Personally I would prefer to run a mixed effects model with restricted maximum likelihood which takes the entire information into account (i.e., the FDA’s code of the 2001 guidance and also in the ABE-part of the progesterone guidance). In this model you could have incomplete data and the variances of R and T are simultaneously estimated. I guess that’s impossible in Excel (as it is in R)…
I got: CVwR 15.86% and CVwT 5.73%. Interesting.

Hope that helps.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
23,056 posts in 4,840 threads, 1,641 registered users;
153 visitors (0 registered, 153 guests [including 81 identified bots]).
Forum time: 17:46 CEST (Europe/Vienna)

Exploratory analysis: The art of finding a Rembrandt
in a Jackson Pollock.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz